Quantcast
Last updated on April 16, 2014 at 8:06 EDT

Latest Exosome Stories

2012-06-04 02:26:09

NEW YORK, June 4, 2012 /PRNewswire/ -- Exosome Diagnostics today announced it has reached agreement with Life Technologies to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in...

2012-05-23 06:25:52

NEW YORK, May 23, 2012 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer. In the first study, the presence of a prostate cancer-specific biomarker in exosomes collected from random patients' urine samples demonstrated a strong...

2012-03-28 02:24:16

NEW YORK, March 28, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today announced that Kapil Dhingra, M.B, B.S., has joined the Exosome Diagnostics Board of Directors. "I am delighted to join the Board of Exosome Diagnostics at this critical stage in the evolution of the company. Cancer treatment is becoming increasingly personalized. The ability to perform repeated,...

2012-02-06 07:00:00

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification...

2012-02-01 07:00:00

MUNICH, Feb. 1, 2012 /PRNewswire/ -- Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to...

2011-10-13 07:00:00

SANTA MONICA, Calif. and NEW YORK, Oct. 13, 2011 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Exosome Diagnostics today are announcing a multi-year collaboration to accelerate clinical validation of Exosome's biofluid molecular diagnostics technology in prostate cancer. In addition, Howard Soule, Ph.D., chief science officer of PCF, will join the Exosome Diagnostics Scientific Advisory Board. The collaboration will explore the capabilities of a new generation of RNA...

2009-11-10 07:00:00

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that Dr. Douglas Taylor has joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced...

2009-10-22 09:30:00

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company. ESI will seek to leverage the recent discovery that the Hemopurifier®, a medical device developed by Aethlon Medical as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas,...

2009-06-22 09:00:00

NEW YORK, June 22 /PRNewswire/ -- Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") today announced that they will collaborate on the development of blood-based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS' industry leading Scorpions(R) real-time PCR Mutation Test Kits in conjunction with ExosomeDX's xOS(TM) technology which harvests high-quality nucleic acids from blood exosomes. The collaboration will...

2008-09-15 09:00:58

Exosome Diagnostics, a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology, has appointed Johan Skog as its new director of genetics research. In this role, Dr Skog will oversee the research program that underlies the company's development of its blood-based diagnostics that can identify cancer-specific genetic mutations. Dr Skog is the primary discoverer and inventor of Exosome Diagnostics's core technology that has been licensed...